359 related articles for article (PubMed ID: 12551822)
21. Prognostic significance of FLT3 ITD and D835 mutations in AML patients.
Sheikhha MH; Awan A; Tobal K; Liu Yin JA
Hematol J; 2003; 4(1):41-6. PubMed ID: 12692519
[TBL] [Abstract][Full Text] [Related]
22. Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia.
Marzac C; Teyssandier I; Calendini O; Perrot JY; Faussat AM; Tang R; Casadevall N; Marie JP; Legrand O
Clin Cancer Res; 2006 Dec; 12(23):7018-24. PubMed ID: 17145823
[TBL] [Abstract][Full Text] [Related]
23. [Correlation of FLT3 gene expression level and internal tandem duplication mutation in acute myeloid leukemia and its clinical significance].
Wang YG; Liu XH; Liang Y; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):741-5. PubMed ID: 19176010
[TBL] [Abstract][Full Text] [Related]
24. FLT3-TKD mutation in childhood acute myeloid leukemia.
Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Wang LY; Chang WH
Leukemia; 2003 May; 17(5):883-6. PubMed ID: 12750701
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.
Yanada M; Matsuo K; Suzuki T; Kiyoi H; Naoe T
Leukemia; 2005 Aug; 19(8):1345-9. PubMed ID: 15959528
[TBL] [Abstract][Full Text] [Related]
26. FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor.
Chillón MC; Fernández C; García-Sanz R; Balanzategui A; Ramos F; Fernández-Calvo J; González M; Miguel JF
Hematol J; 2004; 5(3):239-46. PubMed ID: 15167911
[TBL] [Abstract][Full Text] [Related]
27. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation.
Yoshimoto G; Nagafuji K; Miyamoto T; Kinukawa N; Takase K; Eto T; Kato K; Hayashi S; Kamimura T; Ohno Y; Taniguchi S; Harada M
Bone Marrow Transplant; 2005 Dec; 36(11):977-83. PubMed ID: 16184177
[TBL] [Abstract][Full Text] [Related]
28. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
[TBL] [Abstract][Full Text] [Related]
29. FLT3 mutations do not influence MDR-1 gene expression in acute myeloid leukemia.
Galimberti S; Rossi A; Palumbo GA; Morabito F; Guerrini F; Vincelli I; Fazzi R; Santini V; Petrini M
Anticancer Res; 2003; 23(4):3419-26. PubMed ID: 12926083
[TBL] [Abstract][Full Text] [Related]
30. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications.
Baldus CD; Thiede C; Soucek S; Bloomfield CD; Thiel E; Ehninger G
J Clin Oncol; 2006 Feb; 24(5):790-7. PubMed ID: 16418499
[TBL] [Abstract][Full Text] [Related]
31. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
[TBL] [Abstract][Full Text] [Related]
32. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities.
Bruserud Ø; Hovland R; Wergeland L; Huang TS; Gjertsen BT
Haematologica; 2003 Apr; 88(4):416-28. PubMed ID: 12681969
[TBL] [Abstract][Full Text] [Related]
33. Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16).
Kainz B; Heintel D; Marculescu R; Schwarzinger I; Sperr W; Le T; Weltermann A; Fonatsch C; Haas OA; Mannhalter C; Lechner K; Jaeger U
Hematol J; 2002; 3(6):283-9. PubMed ID: 12522450
[TBL] [Abstract][Full Text] [Related]
34. FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype.
Beran M; Luthra R; Kantarjian H; Estey E
Leuk Res; 2004 Jun; 28(6):547-50. PubMed ID: 15120929
[TBL] [Abstract][Full Text] [Related]
35. Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype.
Palmieri S; Ferrara F; Leoni F; Ciolli S; Pollio F; D'Amico MR; Celentano M; Viola A; Vicari L; Izzo B; Pane F
Hematol Oncol; 2007 Mar; 25(1):1-5. PubMed ID: 17036374
[TBL] [Abstract][Full Text] [Related]
36. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.
Renneville A; Boissel N; Zurawski V; Llopis L; Biggio V; Nibourel O; Philippe N; Thomas X; Dombret H; Preudhomme C
Cancer; 2009 Aug; 115(16):3719-27. PubMed ID: 19536888
[TBL] [Abstract][Full Text] [Related]
37. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children.
Xu F; Taki T; Yang HW; Hanada R; Hongo T; Ohnishi H; Kobayashi M; Bessho F; Yanagisawa M; Hayashi Y
Br J Haematol; 1999 Apr; 105(1):155-62. PubMed ID: 10233379
[TBL] [Abstract][Full Text] [Related]
38. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
[TBL] [Abstract][Full Text] [Related]
39. [Prevalence and clinical significance of FLT3 mutations in acute promyelocytic leukemia].
Xue MX; Qiu HY; Feng YF; Zhu ZL; Chang WR; Liang JY; Chen SN; Cen JN; Xue YQ; Liu YJ; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):757-61. PubMed ID: 19176014
[TBL] [Abstract][Full Text] [Related]
40. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.
How J; Sykes J; Gupta V; Yee KW; Schimmer AD; Schuh AC; Minden MD; Kamel-Reid S; Brandwein JM
Cancer; 2012 Dec; 118(24):6110-7. PubMed ID: 22736495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
